Advertisement
Screener

Humacyte, Inc. (HUMA) Secured Debt, Current

Humacyte, Inc. Secured Debt, Current

Humacyte, Inc. (HUMA) had Secured Debt, Current of $0 as of 2023-12-31, per its 10-K filed 2024-03-28.

Discontinued › Balance Sheet › Liabilities › Long-Term Debt, Current Maturities

us-gaap:SecuredDebtCurrent · last filed 2024-03-28

  • 2023-12-31: Secured Debt, Current $0.00.
  • 2023-09-30: Secured Debt, Current $0.00.
  • 2023-06-30: Secured Debt, Current $0.00.
  • 2023-03-31: Secured Debt, Current $12.86M.
Period endSecured Debt, Current
2023-12-31$0.00
10-K · filed 2024-03-28
2023-09-30$0.00
10-Q · filed 2023-11-09
2023-06-30$0.00
10-Q · filed 2023-08-14
2023-03-31$12.86M
10-Q · filed 2023-05-12
2022-12-31$8.57M
10-K · filed 2024-03-28
2022-09-30$4.29M
10-Q · filed 2022-11-10
2021-12-31$0.00
10-K · filed 2023-03-24
2021-09-30$3.89M
10-Q · filed 2021-11-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
Outlook Therapeutics, Inc. (OTLK)United States$0.162B-4.90
Acumen Pharmaceuticals, Inc. (ABOS)United States$0.162B-1.83
Tenaya Therapeutics, Inc. (TNYA)United States$0.140B-1.60
Voyager Therapeutics, Inc. (VYGR)United States$0.173B-1.99
PRECISION BIOSCIENCES INC (DTIL)United States$0.175B-3.95
Caribou Biosciences, Inc. (CRBU)United States$0.134B-1.79
Armata Pharmaceuticals, Inc. (ARMP)United States$0.132B
Neumora Therapeutics, Inc. (NMRA)United States$0.132B-1.48
enGene Therapeutics Inc. (ENGN)$0.129B-0.92
Coherus Oncology, Inc. (CHRS)United States$0.182B-1.63